These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 17116839

  • 1. Hair depigmentation during chemotherapy with a class III/V receptor tyrosine kinase inhibitor.
    Routhouska S, Gilliam AC, Mirmirani P.
    Arch Dermatol; 2006 Nov; 142(11):1477-9. PubMed ID: 17116839
    [Abstract] [Full Text] [Related]

  • 2. Hair depigmentation during chemotherapy with dasatinib, a dual Bcr-Abl/Src family tyrosine kinase inhibitor.
    Sun A, Akin RS, Cobos E, Smith J.
    J Drugs Dermatol; 2009 Apr; 8(4):395-8. PubMed ID: 19363859
    [Abstract] [Full Text] [Related]

  • 3. Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans.
    Moss KG, Toner GC, Cherrington JM, Mendel DB, Laird AD.
    J Pharmacol Exp Ther; 2003 Nov; 307(2):476-80. PubMed ID: 12966161
    [Abstract] [Full Text] [Related]

  • 4. [Abnormal hair].
    Coen M, Cramer B, Serratrice J.
    Rev Med Interne; 2019 Feb; 40(2):134-135. PubMed ID: 29054584
    [No Abstract] [Full Text] [Related]

  • 5. Reversible hair depigmentation in a patient treated with imatinib.
    Mariani S, Abruzzese E, Basciani S, Fiore D, Persichetti A, Watanabe M, Spera G, Gnessi L.
    Leuk Res; 2011 Jun; 35(6):e64-6. PubMed ID: 21176848
    [No Abstract] [Full Text] [Related]

  • 6. Both Notch1 and Notch2 contribute to the regulation of melanocyte homeostasis.
    Kumano K, Masuda S, Sata M, Saito T, Lee SY, Sakata-Yanagimoto M, Tomita T, Iwatsubo T, Natsugari H, Kurokawa M, Ogawa S, Chiba S.
    Pigment Cell Melanoma Res; 2008 Feb; 21(1):70-8. PubMed ID: 18353145
    [Abstract] [Full Text] [Related]

  • 7. [4-t-butylphenyl]-N-(4-imidazol-1-yl phenyl)sulfonamide (ISCK03) inhibits SCF/c-kit signaling in 501mel human melanoma cells and abolishes melanin production in mice and brownish guinea pigs.
    Na YJ, Baek HS, Ahn SM, Shin HJ, Chang IS, Hwang JS.
    Biochem Pharmacol; 2007 Sep 01; 74(5):780-6. PubMed ID: 17658483
    [Abstract] [Full Text] [Related]

  • 8. Stem cell factor-KIT signalling plays a pivotal role in regulating pigmentation in mammalian hair.
    Hachiya A, Sriwiriyanont P, Kobayashi T, Nagasawa A, Yoshida H, Ohuchi A, Kitahara T, Visscher MO, Takema Y, Tsuboi R, Boissy RE.
    J Pathol; 2009 May 01; 218(1):30-9. PubMed ID: 19214986
    [Abstract] [Full Text] [Related]

  • 9. Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma.
    Sonpavde G, Hutson TE, Sternberg CN.
    Expert Opin Investig Drugs; 2008 Feb 01; 17(2):253-61. PubMed ID: 18230058
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Oral zinc sulphate causes murine hair hypopigmentation and is a potent inhibitor of eumelanogenesis in vivo.
    Plonka PM, Handjiski B, Michalczyk D, Popik M, Paus R.
    Br J Dermatol; 2006 Jul 01; 155(1):39-49. PubMed ID: 16792750
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Stem cell factor/c-Kit signalling in normal and androgenetic alopecia hair follicles.
    Randall VA, Jenner TJ, Hibberts NA, De Oliveira IO, Vafaee T.
    J Endocrinol; 2008 Apr 01; 197(1):11-23. PubMed ID: 18372228
    [Abstract] [Full Text] [Related]

  • 14. New drug therapies for advanced renal cell carcinoma.
    Gore ME, Harrison ML, Montes A.
    Expert Rev Anticancer Ther; 2007 Jan 01; 7(1):57-71. PubMed ID: 17187520
    [Abstract] [Full Text] [Related]

  • 15. Medical treatment options in patients with metastatic renal cell carcinoma.
    Haferkamp A, Hohenfellner M.
    Nephrol Dial Transplant; 2007 Apr 01; 22(4):996-9. PubMed ID: 17210591
    [No Abstract] [Full Text] [Related]

  • 16. Early myeloid cells expressing c-KIT isoforms differ in signal transduction, survival and chemotactic responses to Stem Cell Factor.
    Young SM, Cambareri AC, Odell A, Geary SM, Ashman LK.
    Cell Signal; 2007 Dec 01; 19(12):2572-81. PubMed ID: 17855052
    [Abstract] [Full Text] [Related]

  • 17. Opportunities and obstacles to combination targeted therapy in renal cell cancer.
    Sosman JA, Puzanov I, Atkins MB.
    Clin Cancer Res; 2007 Jan 15; 13(2 Pt 2):764s-769s. PubMed ID: 17255307
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma.
    Oudard S, Medioni J, Aylllon J, Barrascourt E, Elaidi RT, Balcaceres J, Scotte F.
    Expert Rev Anticancer Ther; 2009 Jun 15; 9(6):705-17. PubMed ID: 19496707
    [Abstract] [Full Text] [Related]

  • 20. Rapid hair depigmentation in patient treated with pazopanib.
    Šeparović R, Pavlović M, Silovski T, Tečić Vuger A.
    BMJ Case Rep; 2018 Aug 23; 2018():. PubMed ID: 30139781
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.